Biotech and Women’s Health Funding Is Shifting: Here Is How to Win
The VC landscape is shifting, but women’s health is still being neglected. Here are some ways for founders to adapt and stand out.
The biotech and women's health funding landscape in 2025 is a study in contrasts. On one hand, innovation is exploding, from AI-driven diagnostics to precision medicine. On the other hand, women’s health startups continue to be chronically underfunded, ignored by an investor class that still does not see the entire market opportunity.
This year marks a critical inflection point. With venture capital tightening and market volatility persisting, biotech and women’s health founders need to know what is changing, what is staying the same, and how to play smarter.
Investors Are Still Overlooking a Trillion-Dollar Market
The global women's health market is projected to reach $103 billion by 2030. Still, only 2% of healthcare VC funding has historically gone to women’s health startups (McKinsey & Company, 2023). The WHAM Report makes a compelling case: doubling investment in women-focused research could generate $14 billion in economic and societal gains.
Moreover, women’s health isn’t just reproductive care. Ninety-five percent of conditions affecting women also affect men, but the nuance in care remains absent. Despite that, many VCs still dismiss women’s health as a niche.
Meanwhile, biotech remains volatile but promising. While 2023–2024 saw a slowdown, 2025 is experiencing renewed momentum in AI-powered therapeutics, diagnostics, and longevity tech.
Biotech and Women’s Health Funding Is Evolving Fast
Women’s health and biotech aren’t just having a moment; if we can shift the narrative, they’re on the brink of a funding revolution.
1. Investor Scrutiny Is Increasing
Gone are the days of lofty promises without proof. Investors now demand a more straightforward path to profitability. Startups with strong clinical validation, scalable business models, and thoughtful regulatory strategies are more likely to secure funding.
Women’s health companies addressing chronic conditions, like cardiovascular disease and endometriosis, are gaining traction due to their data-driven economic impact (WHO, 2024).
2. AI and Tech Are Unlocking New Pathways
AI-driven diagnostics, maternal health monitoring, and digital clinical trials are capturing investor interest. Founders who prove AI improves accuracy, shortens timelines, or reduces costs have a distinct edge (Rock Health, 2024).
3. Women Investors Are Gaining Power
Female-led funds like Portfolia and RH Capital are helping shift the balance. And data shows they are right: Women-led startups outperform in capital efficiency and revenue generation yet still get a fraction of the funding (Harvard Business Review, 2024). That gap is beginning to close, but it remains wide.
The Biases That Still Block the Money
Despite market data and demand, outdated perceptions shape who gets funded and who gets ignored.
1. Bias Still Shapes the Table
Structural bias in venture capital hasn’t disappeared. Male-dominated firms continue to underestimate or overlook women’s health altogether. Founders must bring proof, polish, and persistence to every pitch (Crunchbase, 2024).
2. Regulatory Hurdles Are Still High
While the FDA is fast-tracking specific AI applications, digital health remains heavily regulated. Startups must build a regulatory strategy into their go-to-market plans from the outset.
3. Exits Remain Elusive
IPO activity is minimal. Strategic acquisitions are increasing, but only for companies with precise revenue models and scale potential. Founders must approach growth with exit-readiness in mind.
What Smart Founders Are Doing Differently This Year
In a tighter market, founders are not just pitching; they’re positioning. Here is what’s working.
Build a bulletproof business case: Investors want market size, adoption, and revenue data. Founders who show the economic impact of their solution, from cost savings to improved health outcomes, will stand out.
Target the right investors: Look for funds with a proven track record in biotech or women’s health. Don’t waste time convincing the wrong audience.
Use AI and tech to scale smarter: Demonstrate how innovation enhances outcomes and streamlines delivery.
Diversify funding: Grants, corporate partnerships, and non-dilutive capital are increasingly essential in a tighter VC climate.
Why This Moment Could Redefine the Future of Health
Biotech and women’s health aren’t fringe sectors. They’re the future of medicine and the most intelligent investments of the decade.
Investors who get in now will be in charge of transforming healthcare for everyone. Those who don’t will be left behind.
If you're a founder, investor, or advocate shaping the future of healthcare, let's connect. I work with startups navigating this landscape, believing innovation only matters when it reaches the people who need it.
Subscribe to my Substack or connect on LinkedIn to stay in the loop.